Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T14:06:30.704Z.
Calculation as of: 2026-10-06T14:06:30.704Z.
Quote observation: 2026-10-06T14:05:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1e589d4888711efc6e495fe73fbc3b606428562d81b06b8c422d1cee3adbcc2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Establishment Labs Holdings Inc.
Market Cap
$1.95B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.01B
EV/EBITDA Ratio
11.12x
TTM Avg
18.29x
3Y Avg
26.08x
5Y Avg
26.08x
Market Cap
$1.89B
EV/EBITDA Ratio
170.26x
TTM Avg
162.32x
3Y Avg
213.45x
5Y Avg
213.45x
Market Cap
$2.02B
EV/EBITDA Ratio
26.92x
TTM Avg
33.53x
3Y Avg
86.79x
5Y Avg
86.79x
Market Cap
$2.02B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.95B | N/A | N/A | N/A | N/A |
| Immunome, Inc. (IMNM)vs › | $1.99B | N/A | N/A | N/A | N/A |
| AxoGen, Inc. (AXGN)vs › | $2.00B | N/A | 616.50x | 557.10x | 557.10x |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.01B | 11.12x | 18.29x | 26.08x | 26.08x |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 170.26x | 162.32x | 213.45x | 213.45x |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.02B | 26.92x | 33.53x | 86.79x | 86.79x |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.02B | N/A | N/A | N/A | N/A |
| Absci Corporation (ABSI)vs › | $1.84B | N/A | N/A | N/A | N/A |
| Azenta, Inc. (AZTA)vs › | $2.03B | 55.45x | 24.79x | 97.87x | 107.08x |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | N/A | 40.61x | 40.61x | 40.61x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
